Pemvidutide: Altimmune's GLP-1/Glucagon Dual Agonist — Promising or Unproven?

The weight-loss drug race is crowded, and pemvidutide is one of the names that rarely gets its own page — search for it and you mostly find it grouped with survodutide and the rest of the pipeline. So what did the trials actually report about Altimmune's dual agonist, and how far is it from anything a person could use? Here is the honest map of where the evidence stands.

What researchers actually studied

Pemvidutide, also labeled ALT-801, is a synthetic peptide engineered to act on two receptors at once: GLP-1 (the pathway behind approved drugs like semaglutide) and glucagon, which is thought to add an energy-expenditure and liver-fat angle on top of appetite reduction. In the MOMENTUM Phase 2 obesity trial, the sponsor reported average weight reductions around 15.6 percent at 48 weeks at the highest dose studied, with an emphasis on preserving lean mass — figures reported in the trial, not independently established as a class-beating result.

The MASH angle

Beyond obesity, pemvidutide has been explored for metabolic dysfunction-associated steatohepatitis, or MASH — a fatty-liver condition with few good options. The glucagon half of the molecule is the reason researchers are interested here, since it is associated with liver-fat mobilization in studies. Altimmune's IMPACT Phase 2b MASH program reported liver-fat and fibrosis-related endpoints; as with the obesity data, these are early, sponsor-reported figures from mid-stage trials, not confirmed outcomes from completed Phase 3 studies.

What the evidence does not show

No large, completed Phase 3 trial has established pemvidutide's long-term safety or how it stacks up head-to-head against approved GLP-1 drugs or its investigational rivals. The reported weight and liver figures come from mid-stage studies with limited follow-up, so durability, rare adverse events, and real-world tolerability remain open questions. Cross-trial comparisons to survodutide, retatrutide, or tirzepatide are not apples-to-apples, and nothing here supports using pemvidutide outside a clinical trial.

Known and theoretical risks

As with other incretin-based agents, the most commonly reported side effects in pemvidutide trials have been gastrointestinal — nausea, vomiting, and diarrhea, generally reported as mild to moderate and more frequent during dose escalation. The glucagon component raises theoretical questions around heart rate and glycemic effects that ongoing trials are designed to monitor. Because the human data is still early, the full safety profile is not characterized. Separately, any gray-market product sold as pemvidutide carries contamination, sterility, and mislabeling risks that no trial can vouch for.

Regulatory status

Pemvidutide is an investigational drug. It is not FDA-approved, has not been shown safe or effective in humans to a regulatory standard, and is not available or legal for human use outside of a registered clinical trial. Any figures discussed here are reported from those trials and are not instructions or endorsements for use.

References & sources

1. Altimmune, Inc. MOMENTUM — a Phase 2, multicenter, randomized, double-blind, placebo-controlled 48-week study of pemvidutide (ALT-801) in obesity/overweight. ClinicalTrials.gov identifier NCT05295875.
2. Altimmune, Inc. IMPACT — a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH/NASH). ClinicalTrials.gov identifier NCT05989711.
3. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. Journal of Hepatology. 2025 (Epub 2024 Jul 11). PMID 39002641.